# Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer

> **NCT06231771** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Supergenics Life Science Sdn. Bhd.** · enrollment: 22 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Allogeneic mesenchymal stem cells (MSCs)
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06231771
- **Lead sponsor:** Supergenics Life Science Sdn. Bhd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05
- **Primary completion:** 2024-10
- **Final completion:** 2024-12-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06231771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06231771, "Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06231771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*